Patrick Hsu
Angel Investor @ NFDG Ventures
Cambridge, United States
Patrick Hsu is a seed investor at NFDG Ventures in Cambridge focused on Health Care and Biotechnology. Patrick Hsu
- Total investments:
- 6
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Patrick Hsu invests in
Stages Patrick Hsu invests in
Countries Patrick Hsu invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 2 (33%)
- Biotechnology 2 (33%)
- Medical 1 (17%)
- Software 1 (17%)
- Clinical Trials 1 (17%)
Stage
- Seed 2 (33%)
- Series A 1 (17%)
- Series B 1 (17%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Traversal is building the AI SRE for the enterprise. | $48M / Series A / Jun 18, 2025 | ||
| Developing better genetic medicines, built with AI. | Seed / Jan 13, 2025 | ||
| Vial was founded to execute on a mission to reimagine clinical trials by delivering faster and more efficient trials for sponsors. Vial’s powerful technology platform delivers faster, more efficient trials that are up to 50% cheaper. | $67M / Series B / Nov 30, 2022 | ||
Nucleus
|
Nucleus provides genetic analysis of greater breadth, depth, and beauty. Users can upload their genetic information obtained through an established company. The proprietary algorithms will calculate polygenic risk scores and measure disease risk based on analysis of genetic variants and display them in a user-friendly platform. | $14M / Seed / Jul 14, 2022 | |
|
Nucleus
|
Nucleus provides genetic analysis of greater breadth, depth, and beauty. Users can upload their genetic information obtained through an established company. The proprietary algorithms will calculate polygenic risk scores and measure disease risk based on analysis of genetic variants and display them in a user-friendly platform. | $3.5M / Seed / Dec 15, 2021 | |
| See all 6 investments → | |||
Co-Investors
About NFDG Ventures
NFDG Ventures is a venture capital firm of Nat Friedman and Daniel Gross.
NFDG Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Leonard Bogdonoff
Investor
|
|||
Nat Friedman
Founder and Managing Partner
|
|||
Nat Friedman
Founder and Managing Partner
|
|||
Nat Friedman
Founder and Managing Partner
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Patrick Hsu invest in?
Patrick Hsu invests primarily in Health Care, Biotechnology and Medical startups, most often at Seed and Series A stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Patrick Hsu?
Public channels for Patrick Hsu include LinkedIn and X (Twitter). For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Patrick Hsu last invest?
The most recent investment recorded for Patrick Hsu closed in Jun 2025. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
